Generic Name: sunitib
Drug Class: Targeted Therapy Medications
Approval Status: Approved
Generic Version Available: No
Experimental Code: SU11248
Sutent is a kinase inhibitor approved for treatment of gastrointestinal stromal tumor, pancreatic neuroendocrine tumors and advanced kidney cancer (renal cell carcinoma), and for adjuvant treatment of high-risk kidney cancer after surgery.
Sutent is a kinase inhibitor that blocks the action of several enzymes, including PDGFR, VEGFR, KIT and RET, that play a role in cancer cell growth and development of blood vessels that feed tumors.
Studies showed that Sutent delayed disease progression in people with gastrointestinal stromal tumor, pancreatic neuroendocrine tumors and advanced kidney cancer. The S-TRAC trial found that adjuvant therapy with Sutent improved disease-free survival compared with placebo after kidney removal. Sutent was first approved in 2006.
Sutent is given as a once-daily tablet.
Common side effects include fatigue, weakness, diarrhea, mouth sores, nausea, vomiting, loss of appetite, bleeding, altered taste sensation, low platelet count (thrombocytopenia) and hand-foot syndrome (palmar-plantar erythrodysesthesia), with redness, swelling and pain on the palms of the hands and soles of the feet. Potential serious side effects may include liver and heart problems, high blood pressure, severe thrombocytopenia, osteonecrosis of the jaw, severe skin reactions, thyroid problems, elevated blood glucose, slow wound healing and tumor lysis syndrome, a reaction that can occur when cancer cells die suddenly. Sutent may cause fetal harm if used during pregnancy.
For More Info: https://www.sutent.com/
Patient Assistance Program Info: https://www.sutent.com/help-paying-for-sutent
Last Reviewed: March 24, 2019